A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor
Autologous transplantation of hematopoietic stem cells (HSCs) is a widely used strategy for hematologic and immunologic recovery after high-dose chemotherapy for hematologic malignancies, such as multiple myeloma (MM), non-Hodgkin lymphoma, Hodgkin disease, and other cancers, including germ cell tumor and neuroblastoma [1]. After chemotherapy induction, regardless of whether or not the chemotherapy has been accompanied by cytokine (usually granulocyte colony stimulating factor [G-CSF]) treatment, or after the patient has received treatment with a cytokine alone (such as G-CSF) without associated chemotherapy, HSCs for transplantation are usually obtained from the peripheral blood.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Hareth Nahi, Marina Celanovic, Qianying Liu, Johan Lund, Valdas Peceliunas Source Type: research
More News: Allergy & Immunology | Biology | Brain | Cancer | Cancer & Oncology | Chemotherapy | Germ Cell Tumors | Hematology | Hodgkin's Disease | Lymphoma | Myeloma | Neuroblastoma | Neurology | Non-Hodgkin's Lymphoma | Stem Cell Therapy | Stem Cells | Study | Transplants